Zentalis contributes $1 million to SU2C Catalyst program for research into targeted c
 

Stand Up To Cancer and Zentalis Pharmaceuticals, Inc. today announced that Zentalis will contribute $1 million to the SU2C Catalyst program to support research that investigates the use of certain small molecule inhibitors for treating a variety of cancer types.

More...